Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 14;23(7):704–717. doi: 10.1016/j.neo.2021.05.006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Identification of RASGRF1 and TROAP as the potential key genes. (A) Intersection of DEGs and CNVCor genes contains two key genes: RASGRF1 and TROAP. (B) RASGRF1 expression was lowly expressed in Cluster1 (p=5.4e-24), and TROAP was highly expressed in Cluster1 (p=8.687e-52). (C) RASGRF1 expression was lowly expressed in tumor tissue (p=1.641e-26), and TROAP was highly expressed in tumor tissues (p=2.92e-31). (D) The association between gene copy-number alterations and transcript levels using cBioportal. (E) Relative expression level of RASGRF1 and TROAP in different clinical stages. Statistical test: Kruskal-Wallis test. (F) Survival analysis with Kaplan-Meier plot shows that patients with high RASGRF1 expression had an obviously longer OS (HR=0.63, p=0.0036) than those with low RASGRF1 expression, and longer DFS (HR=0.75, p=0.071) without any statistical significance; (G) Patients with high TROAP expression had a significantly shorter OS (HR=2.19, p<0.0001) and DFS (HR=1.85, p=9e-04) than those with low TROAP expression. (H) GSE31210 dataset was chosen to further verified the prognostic values of RASGRF1 and (I) TROAP. P-values were calculated using the log-rank test.